-The Times of India     The three-year compliance period for the Right to Education (RTE) Act is just over. What has the Act accomplished? Sadly, not very much that is positive. A key provision in the law abolishes board examinations and grants automatic promotion to each child to the next grade at the end of the academic year. It also requires the award of a diploma to all at the end of eight...

-Live Mint Reimbursing schools that reserve 25% seats for underprivileged children may end up costing the govt about Rs.16,000 cr The central government is faced with the prospect of a large bill to pay for the implementation of one of the key elements of the right to education (RTE) legislation-reimbursing private schools that reserved 25% of their seats for underprivileged children-even as the 31 March deadline for most of the law's other...

-The Indian Express India is no insecure dictatorship junking international obligations for cheap populism. The highest court of the world's largest democracy has made a nuanced distinction between real innovation and marketing gimmickry. Yet, the Swiss pharmaceutical giant Novartis's response to the recent Supreme Court verdict in Novartis vs Union of India has been imperial in tone. The judgment "discourages innovative drug discovery", it claimed. It accused Indian law of lagging...

-The Hindu Considering the knowledge of English as a mark of social advancement and that of the vernacular as backwardness disenfranchises significant sections of society In a village in Ghazipur district that borders Varanasi, there is a young man who teaches English and "personality development" to the sons and daughters of local shopkeepers, farmers and truck drivers. The classes are held from 6 to 8 in the morning and again in the...

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...